BJMO - volume 12, issue 3, may 2018
L. Decoster MD, PhD, H. Rouvière MD, C. Kenis PhD, MSc
The 2017 annual conference of the International Society of Geriatric Oncology took place in Warsaw, Poland from November 9–11th. More than 300 delegates from 42 countries with a special interest in the care for older patients with cancer attended this conference. The meeting provided an overview of current advances in geriatric oncology.
(BELG J MED ONCOL 2018:12(3):142–144)
Read moreBJMO - volume 12, issue 10, march 2018
M. Albersen MD, PhD, MD , PhD
It has become of yearly tradition of BMUC to put a tumor type in the spotlight that is often overlooked at (inter)national symposia. This year, Prof. Maarten Albersen gave an overview of the current treatment landscape of penile cancer.
BJMO - volume 12, issue 10, march 2018
No authors
2018 Marked the 5th edition of the Belgian Multidisciplinary Meeting on Urological Cancers (BMUC). This meeting is a collaboration between the BSMO, BVU/SBU, and BVRO/ABRO and took place on 9 and 10 March 2018. We invited Prof. Sylvie Rottey (BMUC President) to share her thoughts on the achievements of BMUC and of the future plans with the organization.
Read moreBJMO - volume 12, issue 10, march 2018
A. de la Taille
Data regarding the natural history of prostate cancer (PCa) disease confirm the clinical insignificance of low-grade prostate cancer, which is associated with scant or no metastatic dissemination. Active surveillance (AS) is a conservative management approach, conducted for patients with “low-” or “favorable-risk” disease, which avoids long-term adverse effects on the patient’s quality of life. In a lecture during BMUC 2018, Prof. de la Taille explained why he thinks that AS is an option that we need to consider and why we should discuss this with the patient before the biopsy is taken.
BJMO - volume 12, issue 10, march 2018
Prof. P. Ost , PhD and Prof. B. Tombal
In a pro and con debate, Prof. Piet Ost and Prof. Betrand Tombal discussed the potential of metastasisdirected therapy for patients with oligorecurrent prostate cancer.
BJMO - volume 12, issue 10, march 2018
A. de la Taille
Over the last 10 years we have witnessed a revolution in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The introduction of several new therapeutic modalities had a significant impact on the overall survival (OS) of these patients. Whereas the median OS for patients with mCRPC was only 24.2 months back in 1997, this has increased to 39.4 months in a patient cohort from 2007 to 2013. This represents an increase in the median OS with 1.5 years.1 Currently, patients with mCRPC have 6 different drugs at their disposal. The question now is: “how to best sequence these different options?”
BJMO - volume 12, issue 10, march 2018
D. De Maeseneer MD, F.X. Otte MD, S. Albisinni MD
ASCO GU represents one of the yearly highlights in the field of genitourinary cancer. During BMUC 2018 the key data presented at this meeting were summarized.
Top
